Skip to main content
. 2023 May 8;13(9):2757–2773. doi: 10.7150/thno.81406

Figure 3.

Figure 3

Anti-HMGB1 neutralizing antibody protects against post-RLDC kidney injury and fibrosis. C57BL/6 mice received a weekly injection with 8 mg/kg cisplatin for four weeks. After the last cisplatin injection, anti-HMGB1 antibody or control IgG were injected daily for one week for sample collection and analysis. (A) Representative tracing of FITC-sinistrin clearance to indicate glomerular filtration rate (GFR). (B) Summary of GFR measured by FITC-sinistrin clearance. (C) Representative renal histology of hematoxylin and eosin (HE)-staining showing the beneficial effect of anti-HMGB1 antibody in RLDC-treated mice. Scale bar = 50 μm. (D) Kidney tubule damage score. (E) Representative images of Masson's trichrome staining of kidney tissues. Scale bar = 50 μm. (F) Quantification of the collagen positive area according to MASSON staining. (G) Representative immunoblots of FN, VIM and GAPDH in kidney tissues. (H) Densitometric analysis of FN and VIM protein levels in immunoblots. Quantitative data are expressed as mean ± SEM. N = 5. * P <0.05 vs. the untreated control group (Con); # P < 0.05 vs. RLDC/IgG group.